Works on a new EUR13M warehousing project underway at Actavis in Malta

Over the coming months Actavis Ltd in Malta will be investing a total of EUR13M for the construction of a new warehouse adjacent to the plant.

This investment is being made with the support of Malta Enterprise and the Ministry of the Finance, Economy and Investment.

This was announced by Actavis’ managing director in Malta, Patrick Cachia during a visit to the facility in Zejtun by the Maltese Prime Minister, Dr Lawrence Gonzi.

Cachia added that, "the new warehouse will provide the required platform and infrastructure to the manufacturing site for future growth. This is strategically important for the Actavis Group since it is one of the main key launch sites for new products. The new warehouse will have a built up area of around 5000sq metres and maximum capacity of 7500 pallet locations.“

Together with the management team, Cachia accompanied the Prime Minister and his delegation on a tour of the premises including the offices and the laboratories. Cachia explained that, “Actavis is one of the global leaders in the production of generic pharmaceuticals. The Malta facility is a key site to the Actavis group through strong customer service, first-to market launches, strong GMP and EHS commitment whilst maintaining a cost competitive edge through a continuous improvement philosophy. This year the company has increased its packaging capacity further by employing another 20 employees to have all of its 10 packaging lines to work on a 4 shift. The company in Malta also boasts of a research and development unit which employees 53 highly skilled employees. The Malta plant employs a total 603 people.”

Following the tour of the premises, Dr Gonzi also had the opportunity to meet the company’s employees at the canteen, where they had a chance to ask questions on issues of general concern during an informal round table meeting.

Actavis is presently undergoing an integration process with the Watson group and after the deal is complete by the end of the year, it will become the third largest generic company worldwide.